TrioBiotics Pharma AG
Triton BioPharma commences Commercial Sale of Marine-Derived Fine Chemicals
Triton Biopharma AG / Product Launch Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- ZUG, Switzerland - March 25, 2009 - TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced that its wholly owned subsidiary, Triton BioPharma LLC, has begun sales of its inventory of fine chemicals. The University of Mississippi licensed the initial repository of marine natural products to Triton, and the company will continue to grow the volume and diversity of these fine chemicals through its research and development activities. Triton's research chemicals represent high value and high quality marine natural products produced under GLP conditions. With expertise in isolation of milligram to kilogram quantities of biologically active molecules from natural sources, the company has the expertise to high purity unique metabolites from marine organisms. These materials are to be utilized by Triton primarily as starting material in its own drug discovery efforts and, secondarily, controlled quantities of these compounds are made available for sale on a wholesale and retail basis as specialized reagents and pharmacological tools. This inventory will be closely managed and sold on a small scale due to the limiting cost of production and to protect the research value of the marine natural products utilized in Triton's own research activities. 'We anticipate that Triton will become the leading wholesaler and retailer for marine derived fine chemicals', said Angelo Boujos, Chairman and CEO of Triton BioPharma AG. 'Although Trion's fine chemicals may represent an enormous commercial value in the hundreds of millions of dollars, we believe that the development potential of these marine natural products for new drugs far exceeds its commercial value as its true worth.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton's biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. Triton's current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com Contact: Investor Relations Europe: Milestone Media AG, Zug, Switzerland Phone: +41 (0)41 5000 769 Fax: +41 (0)41 5000 728 E-mail: info@milestonemedia.ch 25.03.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden